Vasudevan D. Circulating microbiome and its clinical implications in diabetes mellitus: Mechanistic insights and therapeutic perspectives. World J Diabetes 2026; 17(3): 113843 [DOI: 10.4239/wjd.v17.i3.113843]
Corresponding Author of This Article
Dinakaran Vasudevan, PhD, Senior Scientist, Gut Microbiome Division, Scientific Knowledge on Aging and Neurological Ailments (SKAN) Research Trust, Happiest Health Office, No.141/2, Gate 4, St. John’s Research Institute, 100 Feet Road, KHB Block, John Nagar, Koramangala, Bengaluru 560034, Karnataka, India. dinakaran.svgev@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Mar 15, 2026 (publication date) through Mar 15, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Vasudevan D. Circulating microbiome and its clinical implications in diabetes mellitus: Mechanistic insights and therapeutic perspectives. World J Diabetes 2026; 17(3): 113843 [DOI: 10.4239/wjd.v17.i3.113843]
World J Diabetes. Mar 15, 2026; 17(3): 113843 Published online Mar 15, 2026. doi: 10.4239/wjd.v17.i3.113843
Circulating microbiome and its clinical implications in diabetes mellitus: Mechanistic insights and therapeutic perspectives
Dinakaran Vasudevan
Dinakaran Vasudevan, Gut Microbiome Division, Scientific Knowledge on Aging and Neurological Ailments (SKAN) Research Trust, Bengaluru 560034, Karnataka, India
Author contributions: Vasudevan D conceptualized, wrote and revised this manuscript.
Conflict-of-interest statement: The author declares that he has no conflict of interest.
Corresponding author: Dinakaran Vasudevan, PhD, Senior Scientist, Gut Microbiome Division, Scientific Knowledge on Aging and Neurological Ailments (SKAN) Research Trust, Happiest Health Office, No.141/2, Gate 4, St. John’s Research Institute, 100 Feet Road, KHB Block, John Nagar, Koramangala, Bengaluru 560034, Karnataka, India. dinakaran.svgev@gmail.com
Received: September 5, 2025 Revised: December 2, 2025 Accepted: January 14, 2026 Published online: March 15, 2026 Processing time: 189 Days and 1.5 Hours
Core Tip
Core Tip: The circulating microbiome, encompassing microbial DNA, products, and microbial components detected in blood, links gut barrier dysfunction to chronic, low-grade inflammation in diabetes. Quantifying blood microbial signatures (16S rDNA/cell free DNA, endotoxin activity, metabolites) may enable early risk stratification for insulin resistance and prediction of micro- and macrovascular complications. Integrating longitudinal cell-free microbiome profiling with glycemic and inflammatory indices could refine diagnosis, personalize therapy, and monitor responses to interventions (dietary fiber, pre/probiotics, postbiotics, barrier-restoring strategies, and microbiome-informed pharmacotherapy, such as metformin). Standardized sampling, contamination control, and causal studies are critical to translate these insights into routine diabetes care.
